Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.01+0.05 (+0.15%)
Close on Nov 17, 2026Market cap $1.92BP/E 10.7Yield –
Harmony Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Harmony Biosciences's enterprise value was $1.48B on Nov 11, 2026, against $1.53B a year earlier. Over the last 5 years it ranged from $1.01B to $3.43B, with a median of $1.74B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.48B | -10.7% |
| 2025 | Dec 31, 2025 | $1.65B | -4.8% |
| 2024 | Dec 31, 2024 | $1.73B | +1.0% |
| 2023 | Dec 29, 2023 | $1.72B | -45.5% |
| 2022 | Dec 30, 2022 | $3.15B | +26.4% |
| 2021 | Dec 31, 2021 | $2.49B | +23.0% |
| 2020 | Dec 31, 2020 | $2.03B | – |
See a number that looks wrong?